

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/566,150
				Filing Date	October 7, 2009
				First Named Inventor	Yusheng Wu
				Art Unit	1624
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	26505-526 NATLUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A*	US-20020169191	11-14-2002	Gordeev et al.	
	B*	US-20020183371	12-05-2002	Gordeev et al.	
	C*	US-20030144263	07-31-2003	Gravestock	
	D*	US-20030166620	09-04-2003	Lee et al.	
	E*	US-20040132764	07-08-2004	Locher	
	F*	US-20050038092	02-17-2005	Fukuda	
	G*	US-20050043317	02-24-2005	Zhou et al.	
	H*	US-20060270637	11-30-2006	Gravestock et al.	
	I*	US-20070197541	08-23-2007	Oyelere et al.	
	J*	US-4,348,393	09-07-1982	Bourgery et al.	
	K*	US-4,948,801	08-14-1990	Carlson et al.	
	L*	US-5,043,443	08-27-1991	Carlson et al.	
	M*	US-5,130,316	07-14-1992	Carlson et al.	
	N*	US-5,254,577	10-19-1993	Carlson et al.	
	O*	US-5,523,403	06-04-1996	Barbachyn	
	P*	US-5,565,571	10-15-1996	Barbachyn et al.	
	Q*	US-5,627,181	05-06-1997	Riedl et al.	
	R*	US-5,654,428	08-05-1997	Barbachyn et al.	
	S*	US-5,654,435	08-05-1997	Barbachyn et al.	
	T*	US-5,684,023	11-04-1997	Riedl et al.	
	U*	US-5,756,732	05-26-1998	Barbachyn et al.	
	V*	US-5,801,246	09-01-1998	Barbachyn et al.	
	W*	US-5,843,967	12-01-1998	Riedl et al.	
	X*	US-5,922,708	07-13-1999	Riedl et al.	
	Y*	US-5,929,248	07-27-1999	Barbachyn et al.	
	Z*	US-5,981,528	11-09-1999	Gravestock	
	AA*	US-6,239,152	05-29-2001	Gordeev et al.	
	AB*	US-6,271,383	08-07-2001	Gravestock	
	AC*	US-6,365,751	04-02-2002	Gravestock	
	AD*	US-6,441,005	08-27-2002	Gordeev et al.	
	AE*	US-6,495,551	12-17-2002	Betts et al.	
	AF*	US-6,531,470	03-11-2003	Gordeev et al.	
	AG*	US-6,562,844	05-13-2003	Gordeev et al.	
	AH*	US-6,605,630	08-12-2003	Gravestock	
	AI*	US-6,617,339	09-09-2003	Gravestock	
	AJ*	US-6,638,955	10-28-2003	Gravestock	
	AK*	US-6,689,779	02-10-2004	Lee et al.	
	AL*	US-6,821,980	11-23-2004	Guerry et al.	

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/566,150
				Filing Date	October 7, 2009
				First Named Inventor	Yusheng Wu
				Art Unit	1624
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	26505-526 NATLUS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁵ (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		AM DE-10034627-A1	01-31-2002	Bayer Ag		✓
		AN EP-0352781-A2	01-31-1990	Du Pont		✓
		AO EP-0694543-A1	01-31-1996	Bayer Ag		✓
		AP JP-8151577-A	06-11-1996	Canon Kk		✓
		AQ JP-8151578-A	06-11-1996	Canon Kk		✓
		AR WO-0010566-A1	03-02-2000	Squibb Bristol Myers Co		
		AS WO-0021980-A1	04-20-2000	Zeneca Ltd et al.		
		AT WO-0029396-A1	05-25-2000	Bayer Ag et al.		
		AU WO-0109107-A1	02-08-2001	Upjohn Co et al.		
		AV WO-0132633-A1	05-10-2001	Hoffmann La Roche et al.		
		AW WO-0140236-A2	06-07-2001	Astrazeneca Ab et al.		
		AX WO-0142229-A1	06-14-2001	Ortho Mcneil Pharm Inc		
		AY WO-0181350-A1	11-01-2001	Astrazeneca Ab et al.		
		AZ WO-0194342-A1	12-13-2001	Dong A Pharm Co Ltd et al.		
		BA WO-02080841-A2	10-17-2002	Astrazeneca Ab et al.		
		BB WO-02081468-A1	10-17-2002	Astrazeneca Ab et al.		
		BC WO-02081489-A1	10-17-2002	Astrazeneca Ab et al.		
		BD WO-02081470-A1	10-17-2002	Astrazeneca Ab et al.		
		BE WO-02096890-A2	12-05-2002	Astrazeneca Ab et al.		
		BF WO-02096916-A1	12-05-2002	Astrazeneca Ab et al.		
		BG WO-0253560-A1	07-11-2002	Syngenta Participations Ag et al.		
		BH WO-03022824-A1	03-20-2003	Astrazeneca Ab et al.		
		BI WO-03035648-A1	05-01-2003	Astrazeneca Ab et al.		
		BJ WO-03072553-A1	09-04-2003	Upjohn Co et al.		
		BK WO-03072575-A1	09-04-2003	Astrazeneca Ab et al.		
		BL WO-03084534-A1	10-16-2003	Upjohn Co et al.		
		BM WO-04029066-A2	04-08-2004	Rib X Pharmaceuticals Inc		
		BN WO-04048392-A1	06-10-2004	Astrazeneca Ab et al.		
		BO WO-04056817-A1	07-08-2004	Astrazeneca Ab et al.		
		BP WO-04056818-A1	07-08-2004	Astrazeneca Ab et al.		
		BQ WO-04056819-A1	07-08-2004	Astrazeneca Ab et al.		
		BR WO-04078753-A1	09-16-2004	Astrazeneca Ab et al.		
		BS WO-04089943-A1	10-21-2004	Upjohn Co et al.		
		BT WO-05003087-A2	01-13-2005	Orchid Chemicals & Pharm Ltd et al.		
		BU WO-05012270-A2	02-10-2005	Rib X Pharmaceuticals Inc et al.		

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/566,150
(Use as many sheets as necessary)				Filing Date	October 7, 2009
Sheet	3	of	4	First Named Inventor	Yusheng Wu
				Art Unit	1624
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	26505-526 NATLUS

	BV	WO-05012271-A2	02-10-2005	Rib X Pharmaceuticals Inc et al.		
	BW	WO-05019211-A2	03-03-2005	Rib X Pharmaceuticals Inc et al.		
	BX	WO-05058886-A1	06-30-2005	Dong A Pharm Co Ltd et al.		
	BY	WO-05061468-A1	07-07-2005	Rib X Pharmaceuticals Inc et al.		
	BZ	WO-05070904-A2	08-04-2005	Rib X Pharmaceuticals Inc et al.		
	CA	WO-2004048392-A1	06-10-2004	Astrazeneca Ab et al.		
	CB	WO-2004056817-A1	07-08-2004	Astrazeneca Ab et al.		
	CC	WO-200613397-A2	12-14-2006	Rib X Pharmaceuticals Inc et al.		
	CD	WO-9309103-A1	05-13-1993	Upjohn Co		
	CE	WO-9413649-A1	06-23-1994	Upjohn Co et al.		
	CF	WO-9730995-A1	08-28-1997	Zeneca Ltd et al.		
	CG	WO-9854161-A1	12-03-1998	Upjohn Co et al.		
	CH	WO-9910342-A1	03-04-1999	Zeneca Ltd et al.		
	CI	WO-9928317-A1	06-10-1999	Zeneca Ltd et al.		
	CJ	WO-9933839-A1	07-08-1999	Chell Jedang Corp et al.		
	CK	WO-9937630-A1	07-29-1999	Versicor Inc et al.		
	CL	WO-9964416-A2	12-16-1999	Zeneca Ltd et al.		
	CM	WO-9964417-A2	12-16-1999	Zeneca Ltd et al.		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IWF. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. (English Abstract Only)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	CN	Brickner, S. J., "Oxazolidinone Antibacterial Agents", <i>Curr. Pharm. Des.</i> , 2(2):175-194 (1996)	
	CO	Gleave et al., "Synthesis and Antibacterial Activity of [6,6,5] and [6,6,5] Tricyclic Fused Oxazolidinones", <i>Bioorg. Med. Chem. Lett.</i> , 8:1231-1236 (1998)	
	CP	Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-Oxazolidinones. 1. The 'B' Group", <i>J. Med. Chem.</i> , 32(8):1673-1681 (1989)	
	CQ	Himo et al., "Copper(I)-Catalyzed Synthesis of Azoles. DFT Study Predicts Unprecedented Reactivity and Intermediates", <i>J. Am. Chem. Soc.</i> , 127(1):210-216 (2004)	

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/566,150
				Filing Date	October 7, 2009
				First Named Inventor	Yusheng Wu
				Art Unit	1624
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	26505-526 NATLUS

CR	International Search Report and Written Opinion for International Patent Application No, PCT/US2004/024339, dated June 7, 2005, 22 pages	
CS	International Search Report and Written Opinion for International Patent Application No. PCT/US2004/17097, dated September 16, 2005, 21 pages	
CT	Molander et al., "Palladium-Catalyzed Suzuki-Miyura Cross-Coupling Reactions of Potassium Aryl- and Heteroaryltrifluoroborates", <i>J. Org. Chem.</i> , 68:4302-4314 (2003)	
CU	Orgueira et al., "Regioselective synthesis of [1,2,3]-triazoles catalyzed by C(I) generated in situ from Cu(O) nanosize activated powder and amine hydrochloride salts", <i>Tetra. Lett.</i> , 46(16):2911-2914 (2005)	
CV	Park et al., "Antibacterials. Synthesis and Structure -Activity Studies of 3-Aryl-2-Oxazolidinones. 4. Multiply-Substituted Aryl Derivatives", <i>J. Med. Chem.</i> , 35(6):1156-1165 (1992)	
CW	Partial Search Report for International Patent Application No. PCT/2004/017101, dated August 19, 2005, 10 pages	
CX	Partial Search Report for International Patent Application No. PCT/2004/024334, dated August 19, 2005, 11 pages	
CY	Reck et al., "Novel Substituted (Pyridin-3-yl)phenyloxazolidinones: Antibacterial Agents with Reduced Activity against Monoamine Oxidase A and Increased Solubility", <i>J. Med. Chem.</i> , 50:4868-4881 (2007)	
CZ	Rostovtsev et al., "A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective Ligation of Azides and Terminal Alkynes", <i>Angewandte Chemie International Ed.</i> , 41(14):2598-2599 (2002)	
DA	Verkhozina et al., "Synthesis of Polynuclear Nonfused Azoles", <i>Russian J. Org. Chem.</i> , 39(12):1863-1867 (2003)	
DB	Wu et al., "Efficiency and Fidelity in a Click-Chemistry Route to Triazole Dendrimers by the Copper(I)-Catalyzed Ligation of Azides and Alkynes", <i>Angewandte Chemie International Ed.</i> , 43(30):3928-3932 (2004)	
DC	Zurenko et al., "Oxazolidinone Antibacterial Agents: Development of the Clinical Candidates Eperezolid and Linezolid", <i>Exp. Opin. Invest. Drugs</i> , 6(2):151-158 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.